60 related articles for article (PubMed ID: 20085534)
1. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A
Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Kereiakes DJ; Chrysant SG; Izzo JL; Littlejohn T; Melino M; Lee J; Fernandez V; Heyrman R
Cardiovasc Diabetol; 2012 Oct; 11():134. PubMed ID: 23110471
[TBL] [Abstract][Full Text] [Related]
3. Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
Kereiakes DJ; Neutel JM
Drugs R D; 2011 Sep; 11(3):251-7. PubMed ID: 21777013
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.
Greathouse M
Vasc Health Risk Manag; 2006; 2(4):401-9. PubMed ID: 17323594
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
Kereiakes DJ; Chrysant SG; Izzo JL; Littlejohn T; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
J Clin Hypertens (Greenwich); 2012 Mar; 14(3):149-57. PubMed ID: 22372774
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice.
Bramlage P; Zemmrich C; Ketelhut R; Wolf WP; Fronk EM; Schmieder RE
Vasc Health Risk Manag; 2013; 9():475-83. PubMed ID: 24039432
[TBL] [Abstract][Full Text] [Related]
7. Thresholds for Ambulatory Blood Pressure Among African Americans in the Jackson Heart Study.
Ravenell J; Shimbo D; Booth JN; Sarpong DF; Agyemang C; Beatty Moody DL; Abdalla M; Spruill TM; Shallcross AJ; Bress AP; Muntner P; Ogedegbe G
Circulation; 2017 Jun; 135(25):2470-2480. PubMed ID: 28428231
[TBL] [Abstract][Full Text] [Related]
8. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
Bakris GL; Sica D; Weber M; White WB; Roberts A; Perez A; Cao C; Kupfer S
J Clin Hypertens (Greenwich); 2011 Feb; 13(2):81-8. PubMed ID: 21272195
[TBL] [Abstract][Full Text] [Related]
9. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
Bakris GL; Saxena M; Gupta A; Chalhoub F; Lee J; Stiglitz D; Makarova N; Goyal N; Guo W; Zappe D; Desai AS;
JAMA; 2024 Mar; 331(9):740-749. PubMed ID: 38363577
[TBL] [Abstract][Full Text] [Related]
10. Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Kameda R; Nomoto H; Cho KY; Kawata S; Omori K; Takeuchi J; Nagai S; Kurihara Y; Aoki S; Nakamura A; Atsumi T; Miyoshi H
BMJ Open; 2020 Feb; 10(2):e034883. PubMed ID: 32034028
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis.
Iqbal F; Shuja MH; Azam L; Amjad M; Manjee KZ; Ramzan H; Sharif T; Shoaib A; Tahir A; Kumar S; Khatri M; Varrassi G; Mohamad T
Endocr Pract; 2024 May; 30(5):481-489. PubMed ID: 38484937
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension.
Zhang S; Yin Z; Li ZF; Zhang WJ; Sui YG; Xu YL; Zhang HT; Liu XN; Qiu H; Zhao JL; Li JJ; Dou KF; Qian J; Wu NQ
Cardiovasc Drugs Ther; 2023 Oct; ():. PubMed ID: 37828149
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study.
Garg M; Manik G; Singhal A; Singh VK; Varshney RK; Sethi A
Saudi J Med Med Sci; 2020; 8(2):87-94. PubMed ID: 32587489
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and Effectiveness of a Ring-Type Blood Pressure Measurement Device Compared With 24-Hour Ambulatory Blood Pressure Monitoring Device.
Lee H; Park S; Kwon H; Cho B; Park JH; Lee HY
Korean Circ J; 2024 Feb; 54(2):93-104. PubMed ID: 38196118
[TBL] [Abstract][Full Text] [Related]
15. Effects of the DASH Diet and Walking on Blood Pressure in Patients With Type 2 Diabetes and Uncontrolled Hypertension: A Randomized Controlled Trial.
Paula TP; Viana LV; Neto AT; Leitão CB; Gross JL; Azevedo MJ
J Clin Hypertens (Greenwich); 2015 Nov; 17(11):895-901. PubMed ID: 26041459
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar
Cui Z; Qiu Z; Cheng W; Hu W; Ma G; Cai X; Jin Y; Zhao Y; He L; Li Y; Bu P; Chen X; Wang R; Chen L; Dong P; Feng L; Han X; Hong M; Hou Y; Liao M; Wang M; Wang X; Xie J; Xu Y; Wang Z; Huang K; Li Y; Li D; Ji X; Huang J; Wang J; Fang D; Wang J; Tang L; Liu Y; Fu G; Du J; Wang L; Liu M; Ge J
Exp Ther Med; 2024 Feb; 27(2):51. PubMed ID: 38234624
[TBL] [Abstract][Full Text] [Related]
17. Appraisal of Guidelines for the Management of Blood Pressure in Patients with Diabetes Mellitus: The Consensuses, Controversies and Gaps.
Liu M; Zhang S; Chen X; Guo Y; Zhong X; Xiong Z; Lin Y; Zhou H; Huang Y; Zhang Z; Wang L; Zhuang X; Liao X
Diabetes Metab J; 2021 Sep; 45(5):753-764. PubMed ID: 33894700
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory Blood Pressure Parameters Among Men With Hypogonadism Treated With Testosterone Transdermal Therapy.
Efros MD; Kaminetsky JC; Sherman ND; Chan A; Thomas JW
Endocr Pract; 2024 Jun; ():. PubMed ID: 38876182
[TBL] [Abstract][Full Text] [Related]
19. Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty.
Ambrož M; de Vries ST; Sidorenkov G; Hoogenberg K; Denig P
BMJ Open; 2020 Sep; 10(9):e037694. PubMed ID: 32912988
[TBL] [Abstract][Full Text] [Related]
20. How far to reduce blood pressure in patients with diabetes-even after ACCORD, questions remain.
Weber M
J Clin Hypertens (Greenwich); 2010 May; 12(5):321-2. PubMed ID: 20546371
[No Abstract] [Full Text] [Related]
[Next] [New Search]
